Paradigm Biocapital Advisors LP
Q4 2025 13F Holdings
- Locationnew york, NY
- Num holdings
30
- Value ($000)
$3,917,830
- Date Filed02/17/2026
- Form type13F-HR
- CIK0001855655
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
NUVALENT INC | COM | 670703107 | $530.05M | 14 % | 5,269,433 | ||
REVOLUTION MEDICINES INC | COM | 76155X100 | $529.23M | 14 % | 6,644,403 | ||
ARCELLX INC | COMMON STOCK | 03940C100 | $373.21M | 10 % | 5,724,016 | ||
GENMAB A/S | SPONSORED ADS | 372303206 | $216.83M | 6 % | 7,039,834 | ||
TARSUS PHARMACEUTICALS INC | COM | 87650L103 | $209.79M | 5 % | 2,562,154 | ||
ABIVAX SA | SPONSORED ADS | 00370M103 | $191.15M | 5 % | 1,417,473 | ||
OLEMA PHARMACEUTICALS INC | COM | 68062P106 | $188.6M | 5 % | 7,544,172 | ||
VAXCYTE INC | COM | 92243G108 | $187.7M | 5 % | 4,068,020 | ||
SPDR SERIES TRUST | STATE STREET SPD | 78464A870 | $182.9M | 5 % | 1,500,000 | put | |
CIDARA THERAPEUTICS INC | COM NEW | 171757206 | $167.78M | 4 % | 759,565 |
Rows Per Page
10
- 5
- 10
- 20
- 30
- 50
- 100